1 |
NCT02265900 |
Recruiting |
Parkinson's Disease Exercise TMS PET Study |
|
|
Interventional |
Not Applicable |
- Pacific Parkinson's Research Centre
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Change in Dopamine release measured by RAC PET
|
30 |
All |
40 Years to 80 Years (Adult, Senior) |
NCT02265900 |
H14-02200 |
|
November 2014 |
November 2018 |
November 2018 |
October 16, 2014 |
November 7, 2017 |
|
- Pacific Parkinson's Research Centre
Vancouver, British Columbia, Canada
|
2 |
NCT02538315 |
Recruiting |
Using [18F]FDOPA PET/CT to Monitor the Effectiveness of Fetal Dopaminergic Grafts in Parkinson Disease Patients |
|
|
Observational |
|
- University of Saskatchewan
- University of Manitoba
|
Other |
- Observational Model: Case-Control
- Time Perspective: Prospective
|
- Differences (assessed by standard uptake values (SUV)) between pre and post-surgical nigrostriatal uptake of [18F]FDOPA
|
30 |
All |
18 Years and older (Adult, Senior) |
NCT02538315 |
Bio 15-21 |
|
October 2016 |
September 2018 |
September 2018 |
September 2, 2015 |
May 3, 2017 |
|
- University Of Saskatchewan
Saskatoon, Saskatchewan, Canada
|
3 |
NCT03462082 |
Recruiting |
Asymmetric Subthalamic Deep Brain Stimulation for Axial Motor Dysfunction in Parkinson's Disease |
|
- Other: Asymmetric STN-DBS
|
Interventional |
Not Applicable |
|
Other |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Gait velocity
- Postural instability gait dysfunction 1
- Postural instability gait dysfunction 2
- (and 6 more...)
|
27 |
All |
Child, Adult, Senior |
NCT03462082 |
17-5785 |
|
January 22, 2018 |
June 30, 2019 |
June 30, 2019 |
March 12, 2018 |
March 13, 2018 |
|
- Movement disorders Centre, Toronto Western Hospital
Toronto, Ontario, Canada
|
4 |
NCT03406728 |
Not yet recruiting |
Virtual Reality Can be Used to Improve Balance Reducing Dynamic Falls in Those With Parkinson's Disease |
|
- Other: PDSAFEX
- Other: CONTROL
- Device: VIRTUAL REALITY
|
Interventional |
Not Applicable |
- Sun Life Financial Movement Disorders Research and Rehabilitation Centre
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Change in Unified Parkinson's Disease Rating Scale (UPDRS)
- Change in Sensory Organization Tests (SOT- 6)
- Change in the number of Falls utilizing a Fall Calendar
- (and 5 more...)
|
36 |
All |
55 Years to 90 Years (Adult, Senior) |
NCT03406728 |
MDRC |
|
January 21, 2018 |
April 30, 2018 |
May 30, 2018 |
January 23, 2018 |
January 23, 2018 |
|
- Sun Life Financial Movement Disorders Research and Rehabilitation Centre
Waterloo, Ontario, Canada
|
5 |
NCT02809391 |
Not yet recruiting |
Orthotics and Parkinson's Disease: The Acute and Long-term Effects of Increased Somatosensory Feedback |
|
- Device: Orthotics alone
- Device: Orthotics+textured top cover
|
Interventional |
Not Applicable |
- Wilfrid Laurier University
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Crossover Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Change in Postural Sway during Static Stance
- Change in Dynamic Balance, using the Berg Balance Scale, Timed Up and Go, and the Functional Gait Assessment
- Change in Plantar Pressure Distribution
- (and 5 more...)
|
20 |
All |
55 Years to 75 Years (Adult, Senior) |
NCT02809391 |
KR_POG |
|
July 2016 |
January 2017 |
August 2017 |
June 22, 2016 |
June 22, 2016 |
|
- Wilfrid Laurier University
Waterloo, Ontario, Canada
|
6 |
NCT02347254 |
Recruiting |
ExAblate Transcranial MRgFUS for Unilateral Pallidotomy for the Treatment of Parkinson's Disease |
|
- Device: Transcranial ExAblate
|
Interventional |
Not Applicable |
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Number of Device and Procedure related adverse events
- Severity of Device and Procedure related adverse events
|
6 |
All |
18 Years to 80 Years (Adult, Senior) |
NCT02347254 |
PD004 222434 |
|
September 2014 |
December 2018 |
December 2018 |
January 27, 2015 |
March 27, 2018 |
|
- Sunnybrook Health Sciences Centre
Toronto, Ontario, Canada
|
7 |
NCT02914366 |
Recruiting |
Ambroxol as a Treatment for Parkinson's Disease Dementia |
- Parkinson's Disease Dementia
|
- Drug: Ambroxol
- Other: Placebo
|
Interventional |
Phase 2 |
- Lawson Health Research Institute
- Weston Foundation
- University of Western Ontario, Canada
- London Health Sciences Centre
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Changes in the Alzheimer's Disease Assessment Scale-cognitive subscale (ADAS-cog)
- Changes in the ADCS-Clinician's Global Impression of Change (CGIC)
- Changes in the Montreal Cognitive Assessment
- (and 13 more...)
|
75 |
All |
50 Years and older (Adult, Senior) |
NCT02914366 |
R15-006 105234 181033 |
|
November 2015 |
July 2018 |
December 2018 |
September 26, 2016 |
March 7, 2017 |
|
- Parkwood Institute
London, Ontario, Canada
|
8 |
NCT03232996 |
Not yet recruiting |
Evaluation of a Computer Game Based Rehabilitation System for Assessment and Treatment of Balance and Gait Impairments in Individuals With Parkinson's Disease. |
- Parkinson Disease
- Parkinson
|
- Other: Computer game based balance and walking rehabilitation for individuals with Parkinson's Disease
|
Interventional |
Not Applicable |
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Dynamic Standing Balance
- Gait Assessment
- Unified Parkinson Disease Rating Scale (UPDRS)
|
30 |
All |
55 Years to 70 Years (Adult, Senior) |
NCT03232996 |
H2017:225 |
|
September 1, 2017 |
September 1, 2018 |
September 1, 2018 |
July 28, 2017 |
July 28, 2017 |
|
- College of Rehabilitation Sciences, University of Manitoba
Winnipeg, Manitoba, Canada
|
9 |
NCT03025334 |
Recruiting |
tDCS on Parkinson's Disease Cognition |
- Parkinson Disease
- Mild Cognitive Impairment
|
- Device: transcranial direct current stimulation
|
Interventional |
Not Applicable |
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Care Provider, Outcomes Assessor)
- Primary Purpose: Treatment
|
- cognitive performance in neuropsychological tests
|
24 |
All |
40 Years and older (Adult, Senior) |
NCT03025334 |
B2016:052 |
tDCS-PD-fMRI |
March 22, 2017 |
December 2018 |
December 2019 |
January 19, 2017 |
June 1, 2017 |
|
- University of Manitoba
Winnipeg, Manitoba, Canada
|
10 |
NCT02605161 |
Recruiting |
Imaging Blood Brain Imaging Dysfunction in Parkinson's Disease |
- Parkinson's Disease
- Movement Disorders
|
|
Observational |
|
- Ottawa Hospital Research Institute
|
Other |
- Observational Model: Case-Control
- Time Perspective: Prospective
|
- Degree of contrast enhancement
- Permeability of blood brain barrier in the striatum
|
10 |
All |
Child, Adult, Senior |
NCT02605161 |
20150770-01H |
|
November 2015 |
January 2019 |
February 2019 |
November 16, 2015 |
April 17, 2018 |
|
- The Ottawa Hospital
Ottawa, Ontario, Canada
|
11 |
NCT03243214 |
Recruiting |
Effect of Transcranial Magnetic Stimulation on Cognition and Neural Changes in Parkinson's Disease |
- Parkinson's Disease
- Mild Cognitive Impairment
|
- Device: TMS
- Device: Sham-TMS
|
Interventional |
Not Applicable |
- University of Calgary
- Montreal Neurological Institute and Hospital
- McGill University
- Canadian Institutes of Health Research (CIHR)
|
Other |
- Allocation: Randomized
- Intervention Model: Sequential Assignment
- Masking: Triple (Participant, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- TMS stimulation applied to the left DLPFC has a quantifiable effect on cognition
- Change in structural grey and white matter in the brain at baseline compared to after TMS stimulation
- Change in executive functioning measured as BOLD fMRI sequence
- (and 2 more...)
|
64 |
All |
50 Years to 90 Years (Adult, Senior) |
NCT03243214 |
REB15-1689 |
PD-MCI-TMS |
October 24, 2016 |
September 30, 2018 |
September 30, 2018 |
August 8, 2017 |
March 21, 2018 |
|
- University of Calgary, Department of Clinical Neurosciences
Calgary, Alberta, Canada
|
12 |
NCT02637089 |
Recruiting |
Longitudinal Study of Mild Cognitive Impairment in Parkinson's Disease |
- Parkinson's Disease
- Mild Cognitive Impairment
|
|
Observational |
|
- University of Calgary
- Canadian Institutes of Health Research (CIHR)
- Natural Sciences and Engineering Research Council, Canada
- (and 2 more...)
|
Other |
- Observational Model: Case-Control
- Time Perspective: Prospective
|
- Identify which structures in the brain exhibit the highest structural changes and / or BOLD changes correlated to the Z-scores of the neuropsychological assessments
- Change from baseline in Z-scores of different neuropsychological assessments
- Change in Cognitive Ability measured as BOLD fMRI sequence
- (and 6 more...)
|
200 |
All |
60 Years and older (Adult, Senior) |
NCT02637089 |
REB14-2463 |
PD-MCI |
March 28, 2016 |
May 2020 |
May 2020 |
December 22, 2015 |
March 21, 2018 |
|
- University of Calgary, Department of Clinical Neurosciences
Calgary, Alberta, Canada
|
13 |
NCT02385500 |
Recruiting |
Fesoterodine on Urgency Episodes in Parkinson's Disease Population |
- Urinary Bladder, Overactive
- Parkinson Disease
|
- Drug: Fesoterodine
- Drug: Placebo
|
Interventional |
Phase 4 |
- Sir Mortimer B. Davis - Jewish General Hospital
|
Other |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: Double (Participant, Care Provider)
- Primary Purpose: Treatment
|
- Urgency episodes
- Micturitions
- Urgency urinary incontinence episodes
- (and 9 more...)
|
60 |
All |
50 Years to 85 Years (Adult, Senior) |
NCT02385500 |
15-007 |
|
March 2015 |
November 2018 |
December 2018 |
March 11, 2015 |
March 17, 2017 |
|
- Jewish General Hospital
Montreal, Quebec, Canada
|
14 |
NCT02668497 |
Recruiting |
Kinematic Characterization of Upper Limb Parkinson's Disease Tremor for Optimized Botulinum Toxin Type A Therapy |
|
- Drug: Botulinum Toxin Type A
|
Interventional |
Phase 2 |
- Western University, Canada
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Kinematic tremor severity
- Clinical tremor severity
- Accelerometric kinematic tremor severity
- Quality of life measures
|
50 |
All |
18 Years to 80 Years (Adult, Senior) |
NCT02668497 |
107433 |
|
January 2016 |
January 2018 |
|
January 29, 2016 |
November 1, 2016 |
|
- London Health Sciences Centre
London, Ontario, Canada
|
15 |
NCT03111485 |
Recruiting |
Effect of Long-acting Levodopa on Obstructive Sleep Apnea in Parkinson's Disease |
- Parkinson's Disease
- Obstructive Sleep Apnea
|
- Drug: Sinemet CR
- Drug: Placebo oral capsule
|
Interventional |
Phase 4 |
- McGill University Health Center
- Weston Brain Institute
|
Other |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Apnea-hypopnea index (AHI)
- Proportion of patients having adverse events leading to discontinuation of drug (Feasibility and tolerability)
- Oxygenation from polysomnography
- (and 5 more...)
|
42 |
All |
18 Years and older (Adult, Senior) |
NCT03111485 |
MP-37-2017-2573 |
|
December 2016 |
April 2020 |
April 2020 |
April 12, 2017 |
February 12, 2018 |
|
- McGill University Health Centre
Montreal, Quebec, Canada
|
16 |
NCT02382198 |
Recruiting |
Study of Glycopyrrolate for Moderate-to-severe Sialorrhea in Parkinson's Disease |
- Sialorrhea
- Parkinson's Disease
|
- Drug: Glycopyrrolate
- Drug: Placebo
|
Interventional |
Phase 2 |
- Ottawa Hospital Research Institute
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- Mean sialorrhea related-disability at end of treatment (day 90) measured by the patient/caregiver-rated ROMP-saliva.
- Mean score in sialorrhea severity at end of treatment (day 90) measured by the sialorrhea scoring scale
- Proportion of participants with a reduction of severity of sialorrhea in at least one point from baseline to end of treatment (day 90), measured by the MDS-UPDRS, item 2.2.
|
28 |
All |
30 Years and older (Adult, Senior) |
NCT02382198 |
OttawaHRI REB 2015-0043 |
GLYCOPAR |
July 2016 |
October 2018 |
December 2018 |
March 6, 2015 |
April 17, 2018 |
|
- The Ottawa Hospital - Civic Campus
Ottawa, Ontario, Canada - Toronto Western Hospital
Toronto, Ontario, Canada
|
17 |
NCT02552836 |
Recruiting |
Efficacy of Psychotherapy for Depressed Parkinson`s Disease Patients |
- Depression
- Parkinson's Disease
|
- Behavioral: Interpersonal Psychotherapy
- Behavioral: Supportive Psychotherapy
|
Interventional |
Not Applicable |
- Hopital Montfort
- The Ottawa Hospital
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Outcomes Assessor)
- Primary Purpose: Treatment
|
- Hamilton Depression Rating Scale (HAM-A)
- Beck Depression Inventory (BDI)
- Beck Anxiety Inventory (BAI)
- (and 4 more...)
|
80 |
All |
18 Years to 75 Years (Adult, Senior) |
NCT02552836 |
Montfort Hospital |
|
March 2016 |
June 2020 |
December 2020 |
September 17, 2015 |
April 14, 2016 |
|
- The Ottawa Hospital and University of Ottawa
Ottawa, Ontario, Canada - The Ottawa Hospital
Ottawa, Ontario, Canada
|
18 |
NCT02964611 |
Recruiting |
Social Cognition and Personality Changes in Alzheimer's & Parkinson's Disease & Frontotemporal Lobar Degeneration |
- Alzheimer's Disease
- Parkinson's Disease
- Frontotemporal Lobar Degeneration
|
- Behavioral: Observational Study
|
Observational |
|
- University Health Network, Toronto
|
Other |
- Observational Model: Cohort
- Time Perspective: Cross-Sectional
|
- Personality via the Interpersonal Adjectives Scales and differences between AD, PD, and FTLD
- Personality via the Behaviour Inhibition/Approach Scale (BIS/BAS) and differences between AD, PD, and FTLD
- Personality via the Big Five Inventory (BFI) and differences between AD, PD, and FTLD
- (and 11 more...)
|
120 |
All |
50 Years to 90 Years (Adult, Senior) |
NCT02964611 |
12-0451-BE |
|
January 2013 |
December 2017 |
December 2017 |
November 16, 2016 |
October 26, 2017 |
|
- Toronto Western Hospital, University Health Network
Toronto, Ontario, Canada
|
19 |
NCT02209363 |
Recruiting |
Cognition and Obstructive Sleep Apnea in Parkinson's Disease, Effect of Positive Airway Pressure Therapy |
- Parkinson's Disease
- Obstructive Sleep Apnea
|
- Device: auto-adjusting positive airway pressure
- Other: Nasal dilator strips
|
Interventional |
Not Applicable |
- McGill University Health Center
- Canadian Institutes of Health Research (CIHR)
- American Thoracic Society
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Outcomes Assessor)
- Primary Purpose: Treatment
|
- Change in global cognitive function
- Change in non-motor symptoms of Parkinson's disease
- Change in quality of life
- Change in specific domains of neurocognitive function
|
90 |
All |
18 Years and older (Adult, Senior) |
NCT02209363 |
4120 |
COPE-PAP |
April 2015 |
September 2020 |
September 2020 |
August 5, 2014 |
February 12, 2018 |
|
- Jewish General Hospital
Montreal, Quebec, Canada - McGill University Health Centre
Montreal, Quebec, Canada - Montreal Neurological Hospital and Institute
Montreal, Quebec, Canada
|
20 |
NCT03305809 |
Recruiting |
A Study of LY3154207 in Participants With Parkinson's Disease Dementia |
- Parkinson's Disease Dementia
|
- Drug: LY3154207
- Drug: Placebo
|
Interventional |
Phase 2 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- Change from Baseline in the Continuity of Attention (CoA) Composite Score of the Cognitive Drug Research Computerized Cognition Battery (CDR-CCB)
- Change from Baseline on the Alzheimer's Disease Cooperative Study-Clinician Global Impression of Change (ADCS-CGIC) Score
- Change from Baseline on the CDR-CCB Power of Attention (PoA) Composite Score
- (and 12 more...)
|
340 |
All |
40 Years to 85 Years (Adult, Senior) |
NCT03305809 |
16261 I7S-MC-HBEH |
PRESENCE |
November 9, 2017 |
July 12, 2019 |
July 12, 2019 |
October 10, 2017 |
April 18, 2018 |
|
- University of Alabama Birmingham
Birmingham, Alabama, United States - Dignity Health Barrow Neurological Institute
Phoenix, Arizona, United States - Mayo Clinic of Scottsdale
Scottsdale, Arizona, United States - (and 87 more...)
|
21 |
NCT03042416 |
Recruiting |
18F-DOPA PET Imaging: an Evaluation of Biodistribution and Safety |
- Congenital Hyperinsulinism
- Neuroblastoma
- Neuroendocrine Tumors
- (and 2 more...)
|
|
Interventional |
Phase 3 |
- University of Alberta
- Alberta Health Services
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Diagnostic
|
- Immediate safety evaluation
- Delayed safety evaluation
- Delayed safety evaluation - referring physician
- (and 2 more...)
|
400 |
All |
Child, Adult, Senior |
NCT03042416 |
Pro00055342 |
|
June 29, 2017 |
December 31, 2021 |
December 31, 2022 |
February 3, 2017 |
October 26, 2017 |
|
- University of Alberta Hospital
Edmonton, Alberta, Canada
|
22 |
NCT01629043 |
Recruiting |
National Parkinson Foundation Quality Improvement Initiative |
|
|
Observational |
|
- National Parkinson Foundation
|
Other |
- Observational Model: Other
- Time Perspective: Prospective
|
|
10000 |
All |
Child, Adult, Senior |
NCT01629043 |
NPF-QII |
NPF-QII |
July 2009 |
|
|
June 27, 2012 |
May 30, 2017 |
|
- Barrow Neurological Institute - Muhammad Ali Parkinson Center
Phoenix, Arizona, United States - Parkinson's Institute and Clinical Center
Sunnyvale, California, United States - Georgetown University Hospital
Washington, D.C., District of Columbia, United States - (and 21 more...)
|
23 |
NCT02485600 |
Recruiting |
Observational Study Evaluating Long-term Health Outcomes of Canadian DUODOPA-treated Patients |
- Advanced Parkinson's Disease
|
|
Observational |
|
|
Industry |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Change in participant's motor symptoms
- Change in the cognitive functions.
- Change in the Parkinson's Disease Questionnaire (PDQ-39)
- (and 4 more...)
|
200 |
All |
18 Years to 99 Years (Adult, Senior) |
NCT02485600 |
P14-506 |
|
October 19, 2015 |
April 1, 2021 |
April 1, 2021 |
June 30, 2015 |
March 22, 2018 |
|
- University of Calgary
Calgary, Alberta, Canada - GILDR
Edmonton, Alberta, Canada - Univ British Columbia
Vancouver, British Columbia, Canada - (and 13 more...)
|
24 |
NCT02549092 |
Recruiting |
A Study to Examine the Effect of Levodopa-Carbidopa Intestinal Gel (LCIG) Therapy Relative to That of Optimized Medical Treatment (OMT) on Non-motor Symptoms (NMS) Associated With Advanced Parkinson's Disease (PD) |
- Advanced Parkinson's Disease
|
|
Interventional |
Phase 3 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Change in the Modified Parkinson's Disease Sleep Scale (PDSS-2) Total Score
- Change in the Non-Motor Symptoms Scale (NMSS) Total Score
- Columbia-Suicide Severity Rating Scale (C-SSRS)
- (and 13 more...)
|
88 |
All |
30 Years to 99 Years (Adult, Senior) |
NCT02549092 |
M12-927 2014-004865-26 |
|
September 10, 2015 |
November 30, 2018 |
November 30, 2018 |
September 15, 2015 |
February 2, 2018 |
|
- Parkinson's and Movement
Fountain Valley, California, United States - Georgetown University Hospital
Washington, District of Columbia, United States - Boca Raton Regional Hospital
Boca Raton, Florida, United States - (and 30 more...)
|
25 |
NCT03362879 |
Recruiting |
COmedication Study Assessing Mono- and cOmbination Therapy With Levodopa-carbidopa inteStinal Gel |
|
|
Observational |
|
|
Industry |
- Observational Model: Cohort
- Time Perspective: Retrospective
|
- Percentage of patients on Levodopa-Carbidopa Intestinal Gel (LCIG) monotherapy from LCIG initiation to 12 months
- The percentage of patients on LCIG monotherapy from immediately following LCIG initiation to 12 months in participating countries with at least 20 subjects enrolled
- Time from initial LCIG administration to the initiation of LCIG monotherapy
- (and 10 more...)
|
28 |
All |
18 Years to 99 Years (Adult, Senior) |
NCT03362879 |
P16-831 |
COSMOS |
December 14, 2017 |
December 14, 2018 |
December 14, 2018 |
December 5, 2017 |
March 6, 2018 |
|
- Ottawa Hospital
Ottawa, Ontario, Canada - Toronto Western Hospital
Toronto, Ontario, Canada - Hopital Notre Dame
Montreal, Quebec, Canada - (and 19 more...)
|
26 |
NCT02728843 |
Recruiting |
Study of Parkinson's Early Stage With Deferiprone |
|
- Drug: Deferiprone
- Drug: Placebo
|
Interventional |
Phase 2 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Score on the Part III subscale of the Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS)
- Total score on the MDS-UPDRS
- Scores on the Part I, Part II, and Part IV subscales of the MDS-UPDRS
- (and 9 more...)
|
140 |
All |
18 Years to 80 Years (Adult, Senior) |
NCT02728843 |
LA48-0215 |
SKY |
July 2016 |
December 2018 |
October 2019 |
April 5, 2016 |
April 9, 2018 |
|
- Toronto Western Hospital
Toronto, Ontario, Canada - CHU de Bordeaux, Centre Expert Parkinson
Bordeaux, France - CHRU de Caen
Caen, France - (and 18 more...)
|
27 |
NCT02906020 |
Recruiting |
A Global Study to Assess the Drug Dynamics, Efficacy, and Safety of GZ/SAR402671 in Parkinson's Disease Patients Carrying a Glucocerebrosidase (GBA) Gene Mutation |
|
- Drug: GZ/SAR402671
- Drug: Placebo
|
Interventional |
Phase 2 |
- Genzyme, a Sanofi Company
- Sanofi
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Change from baseline in Movement Disorder Society Unified Parkinson's Disease Rating Scale Part II and III score
- Change from baseline in Parkinson's Disease Cognitive Rating Scale
- Change from baseline in Movement Disorder Society Unified Parkinson's Disease Rating Scale Part I, II, and III score
- Change from baseline in Hoehn and Yahr score
|
243 |
All |
18 Years to 80 Years (Adult, Senior) |
NCT02906020 |
ACT14820 2016-000657-12 U1111-1180-6918 |
MOVES-PD |
December 15, 2016 |
March 2021 |
April 7, 2022 |
September 19, 2016 |
April 12, 2018 |
|
- Investigational Site Number 8400011
Scottsdale, Arizona, United States - Investigational Site Number 8400004
La Jolla, California, United States - Investigational Site Number 8400015
New Haven, Connecticut, United States - (and 27 more...)
|
28 |
NCT02542696 |
Recruiting |
An Open-Label Phase 3 Study to Examine the Long-Term Safety, Tolerability and Efficacy of APL-130277 for the Acute Treatment of "OFF" Episodes in Patients With Parkinson's Disease |
|
|
Interventional |
Phase 3 |
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Evaluation of safety and tolerability data collected, including 12-lead ECGs, orthostatic hypotension, oropharyngeal and dopaminergic AEs, and other pertinent safety parameters.
|
226 |
All |
18 Years and older (Adult, Senior) |
NCT02542696 |
CTH-301 2016-000637-43 |
|
August 31, 2015 |
January 1, 2020 |
January 1, 2020 |
September 7, 2015 |
March 22, 2018 |
|
- University of Alabama Birmingham
Birmingham, Alabama, United States - Muhammed Ali Parkinson and Movement Disorder Center/Barrow Neurological Institute
Phoenix, Arizona, United States - Movement Disorders Center of Arizona
Scottsdale, Arizona, United States - (and 59 more...)
|
29 |
NCT03133611 |
Recruiting |
Detecting Parkinson's Disease Through Speech Analysis |
- Parkinson Disease
- REM Sleep Behavior Disorder
|
- Other: Speech assessment
- Other: Routine clinical assessment
|
Interventional |
Not Applicable |
- Czech Technical University in Prague
- General University Hospital, Prague
- University Hospital, Montpellier
- (and 5 more...)
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Diagnostic
|
- Motor Speech Disorder Examination (MSDE)
- MDS Unified Parkinson's Disease Rating Scale (MDS-UPDRS)
- SCOPA-AUT
- Montreal Cognitive Assessment (MoCA)
|
350 |
All |
50 Years to 80 Years (Adult, Senior) |
NCT03133611 |
MJFF-2016-12546 |
|
April 1, 2017 |
June 30, 2018 |
September 30, 2019 |
April 28, 2017 |
May 2, 2017 |
|
- Mayo Clinic
Rochester, Minnesota, United States - Medical University of Innsbruck
Innsbruck, Austria - McGill University Health Centre
Montreal, Quebec, Canada - (and 4 more...)
|
30 |
NCT02252380 |
Recruiting |
ExAblate Transcranial MRgFUS for the Management of Treatment-Refractory Movement Disorders |
- Movement Disorders
- Essential Tremor
- Holmes Tremor
- (and 6 more...)
|
- Device: Transcranial ExAblate System
|
Interventional |
Not Applicable |
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Severity of Device and Procedure Related Complications
|
10 |
All |
18 Years to 85 Years (Adult, Senior) |
NCT02252380 |
MD003 |
|
May 2015 |
December 2018 |
December 2018 |
September 30, 2014 |
March 27, 2018 |
|
- Sunnybrook Health Sciences Centre
Toronto, Ontario, Canada - Toronto Western Hospital
Toronto, Ontario, Canada
|
31 |
NCT02524405 |
Recruiting |
BEAM: Brain-Eye Amyloid Memory Study |
- Alzheimer's Disease
- Mild Cognitive Impairment
- Vascular Cognitive Impairment
- (and 2 more...)
|
- Other: Flutemetamol PET scan
|
Observational |
|
- Sunnybrook Health Sciences Centre
- Brain Canada
- Weston Brain Institute
- (and 6 more...)
|
Other / Industry |
- Observational Model: Cohort
- Time Perspective: Cross-Sectional
|
- Retinal nerve fiber layer thickness
- Amyloid Depostition
- Retinal artery narrowing
- Retinal venular widening
|
320 |
All |
50 Years to 90 Years (Adult, Senior) |
NCT02524405 |
221-2013 |
BEAM |
February 2016 |
March 2019 |
September 2019 |
August 14, 2015 |
November 27, 2017 |
|
- Sunnybrook Health Sciences Centre
Toronto, Ontario, Canada - St. Michael's Hospital
Toronto, Ontario, Canada - University Health Network
Toronto, Ontario, Canada - (and 2 more...)
|